IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-70
SponsorSun Yat-sen University
About this trial
This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.
Eligibility criteria
Qualifiers
Newly histologic diagnosis of nasopharyngeal non-keratinizing carcinoma (WHO II/III);
All genders, range from 18-70 years old;
ECOG score 0-1;
Clinical stage T4N1M0 and T1-4N2-3M0 (AJCC/UICC 8th);
Disqualifiers
Distant metastases;
Keratinized squamous cell carcinoma or basal cell like squamous cell carcinoma;
Have or are suffering from other malignant tumors;
Participating in other clinical trials;
Trial design
Treatments tested in this trial
- Intensity Modulated Radiation Therapy
- Chemotherapy
- Immune checkpoint inhibitor
- Low-dose radiotherapy
Treatment groups
380 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov